Management transactions

Last modified: 2.12.2021

Managers’ transactions

Each manager must notify Optomed and the FIN-FSA of every transaction in the financial instruments of the company conducted on his/her own account.1 The notifications shall be made promptly and no later than three business days after the date of the transaction (T+3).

In light of Optomed’s obligation to publish such information, managers must submit an informal notice to Optomed (sakari.knuutti@optomed.com and lars.lindqvist@optomed.com) on the date of the transaction and that the actual notification is made to Optomed at the latest within two business days after the date of the transaction (T+2).

The notification shall be sent in electronic format to Optomed’s insider administration (sakari.knuutti@optomed.com and lars.lindqvist@optomed.com) and to the FIN-FSA (by sending a secure email at the web page https://securemail.bof.fi to the address johdonkaupat@finanssivalvonta.fi) by using the form approved by the FIN-FSA, which is available at the FIN-FSA’s website (Related Document G) and include the information specified therein. The company’s insider administration may be contacted for further information.

If a manager authorises another person (e.g. an asset manager) to make the notifications on its behalf, information thereof (and the contact details of the relevant authorised persons) shall be submitted to the insider administration in writing. Such authorisation does not relieve the relevant manager from his/her liability.

1 Under MAR, a person’s obligation to notify transactions applies in respect of the relevant person, once a total amount of EUR 5,000 has been reached within a calendar year (the threshold is calculated by adding without netting all transactions conducted within a certain calendar year).However, Optomed recommends that all transactions are notified (also below the threshold). Optomed also intends to publish all transactions notified to Optomed (whether or not the 5,000 euro limit has been reached).

 

Management holdings:

Optomed discloses manager’s transactions as stock exchange releases no later than three business days after the date of the transaction (T+3). The contents of this site are updated at least quarterly.

Board shareholding 11 November 2021:

  Name

Position

 

Own and
controlled shares

Options

 

  Petri Salonen

Chairman of the Board of Directors

4,295

  Simon Guo

Member of the Board of Directors

410

  Seppo Mäkinen

Member of the Board of Directors

1,901

  Anna Tenstam

Member of the Board of Directors

1,901

  Reijo Tauriainen

Member of the Board of Directors

7,067

  Total

15,574

 

Management shareholding 11 November 2021:

  Name

Position

 

Own and
controlled shares

Options

 

  Seppo Kopsala

CEO

185,080

60,000¹

  Niina Huikuri

Vice President, Marketing

40,000²

  Sakari Knuutti

Chief Legal Officer

40,0003

  Lars Lindqvist

Chief Financial Officer

100,0004

  Markku Myllylä

Vice President, Software

180,0005

  Laura Piila

Vice President, Devices

2000

68,0006

  Total

187,080

488,000

 

¹) Of which 40,000 under the 2015 option program and 20,000 under the 2017 option program.
²) Of which 8,000 under the 2018C option program, 26,000 under the 2019D option program and 6,000 under option program 2020A.
3) Of which 20,000 under the 2019C option program, 14,000 under the 2019D option program and 6,000 under option program 2020A.
4) Of which 100,000 under the 2019B option program.
5) Of which 60,000 under the 2018C option program, 60,000 under the 2019A option program and 60,000 under option program 2020A..
6) Of which 18,000 under the 2015 option program, 10,000 under the 2017 option program, 20,000 options under the 2017B option program and 20,000 under the 2019D option program.